Comparing Theravance Biopharma (NASDAQ:TBPH) & Cronos Group (NASDAQ:CRON)

Cronos Group (NASDAQ:CRON) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings.

Earnings & Valuation

This table compares Cronos Group and Theravance Biopharma”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	$146.59 million	8.40	-$9.45 million	$0.20	16.70
Theravance Biopharma	$107.46 million	8.23	$105.89 million	$1.01	16.86

Theravance Biopharma has lower revenue, but higher earnings than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cronos Group and Theravance Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cronos Group	39.08%	4.85%	4.62%
Theravance Biopharma	51.58%	-0.77%	-0.46%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Cronos Group and Theravance Biopharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	0	2	3	0	2.60
Theravance Biopharma	0	8	0	0	2.00

Cronos Group presently has a consensus price target of $2.30, indicating a potential downside of 31.14%. Theravance Biopharma has a consensus price target of $19.40, indicating a potential upside of 13.92%. Given Theravance Biopharma’s higher probable upside, analysts plainly believe Theravance Biopharma is more favorable than Cronos Group.

Insider & Institutional Ownership

8.7% of Cronos Group shares are owned by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are owned by institutional investors. 7.8% of Cronos Group shares are owned by insiders. Comparatively, 7.6% of Theravance Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Cronos Group has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500.

Summary

Cronos Group beats Theravance Biopharma on 8 of the 14 factors compared between the two stocks.

About Cronos Group

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

About Theravance Biopharma

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs.
Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY.
For more information, please visit www.theravance.com.